Document is current
Any future updates will be listed below
-
Authors
Reguzova, Alena
Müller, Melanie
Pagallies, Felix
Burri, Dominique
Salomon, Ferdinand
Rziha, Hanns-Joachim
Bittner-Schrader, Zsofia
Verstrepen, Babs E. https://orcid.org/0000-0002-4666-0798
Böszörményi, Kinga P. https://orcid.org/0000-0001-5330-2617
Verschoor, Ernst J. https://orcid.org/0000-0003-0912-2074
Gerhauser, Ingo
Elbers, Knut
Esen, Meral
Manenti, Alessandro
Monti, Martina https://orcid.org/0000-0002-2173-7269
Rammensee, Hans-Georg https://orcid.org/0000-0003-1614-2647
Derouazi, Madiha https://orcid.org/0000-0001-9412-9558
Löffler, Markus W. https://orcid.org/0000-0003-2513-1317
Amann, Ralf
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 25 September 2024
First Online: 16 October 2024
Competing interests
: R.A., M.Mü. and F.S. have ownership interest in Prime Vector Technologies GmbH. R.A. and H.-J.R. are inventors and patent-holders on recombinant ORFV vector (EP16741595, EP15794491). R.A., M.Mü., F.S., A.R. and F.P. are inventors and patent-holders on ORFV-based SARS-CoV-2 vaccines and uses thereof (EP23730776). M.W.L. is an inventor of patents owned by Immatics Biotechnologies unrelated to this present work and has acted as a paid consultant in cancer immunology for Boehringer Ingelheim. M.M. and A.M. are employees of VisMederi Srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
